The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment

BACKGROUND: Glioblastoma is the most common and aggressive brain tumour in adults with a median overall survival of only 14 months after standard therapy with radiation therapy (IR) and temozolomide (TMZ). In a novel multimodal treatment approach we combined the checkpoint kinase 1 (Chk1) inhibitor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: Patties, Ina, Kallendrusch, Sonja, Böhme, Lisa, Kendzia, Eva, Oppermann, Henry, Gaunitz, Frank, Kortmann, Rolf-Dieter, Glasow, Annegret
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6805470/
https://ncbi.nlm.nih.gov/pubmed/31639020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1434-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados